New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:04 EDTALNYAlnylam initiates Phase 1 clinical trial with ALN-AT3
Alnylam Pharmaceuticals has initiated a Phase 1 study with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders. ALN-AT3 has demonstrated efficacy in animal models of hemophilia, including in non-human primate models of induced hemophilia. Moreover, pre-clinical studies of ALN-AT3 support a wide therapeutic index in the hemophilia setting. ALN-AT3 is a key program in the company’s “Alnylam 5x15” product strategy, which is aimed at advancing multiple RNAi therapeutic genetic medicine programs into clinical development. Alnylam recently announced that it expects to exceed its original “Alnylam 5x15” guidance with six to seven genetic medicine programs in clinical development by the end of 2015, including at least two programs in Phase 3 and five to six programs that will have achieved human proof-of-concept results supporting further development. The Phase 1 study is being conducted in the U.K. as a single- and multi-dose, dose-escalation study consisting of two parts. Part A will be a randomized, single-blind, placebo-controlled, single-dose, dose-escalation study, enrolling up to 24 healthy volunteer subjects. The primary objective of this part of the study is to evaluate the safety and tolerability of a single low dose of ALN-AT3, with the potential secondarily to show changes in AT plasma levels at sub-pharmacologic doses. Part B of the study will be an open-label, multi-dose, dose-escalation study enrolling up to 18 people with moderate to severe hemophilia A or B. The primary objective of this part of the study is to evaluate the safety and tolerability of multiple doses of subcutaneously administered ALN-AT3 in hemophilia subjects. Secondary objectives include assessment of clinical activity as determined by knockdown of circulating AT levels and increase in thrombin generation at pharmacologic doses of ALN-AT3.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:04 EDTALNYAlnylam receives orphan drug designation for revusiran
Subscribe for More Information
May 19, 2015
11:03 EDTALNYAlnylam transthyretin amyloidosis treatment designated for FDA orphan status
Alnylam's revusiran was designated by the FDA for orphan drug status as a treatment of transthyretin amyloidosis. Reference Link
07:28 EDTALNYUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
15:24 EDTALNYAlnylam files ALN-AAT trial application, reports positive results in primates
Subscribe for More Information
May 12, 2015
07:52 EDTALNYLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use